Abstract

The present invention relates to fluorescent dyes of formula (I), including salts thereof, and extracellular vesicles and cells labelled with the fluorescent dyes. The present invention also relates to methods, uses and kits thereof. The present invention relates to fluorescent dyes of formula (I), including salts thereof, and extracellular vesicles and cells labelled with the fluorescent dyes. The present invention also relates to methods, uses and kits thereof.

IPC Classes  ?

• C09B 55/00 - Azomethine dyes
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention relates to aqueous formulations comprising a polyol, a sugar or combination thereof, a non-ionic surfactant, a salt and a buffering agent. The aqueous formulation of the present invention further comprises extracellular vesicles (EVs). The present invention also relates to using said formulations for the preservation, in particular through freezing, and/or the administration of the EVs. Particular exemplified embodiments comprise 5% w/v sucrose or 12.5% w/v trehalose, 20 mM histidine, 150 mM NaCl and 0.01-0.2% w/v Polysorbate 20 with a pH of 6.0. These formulations can further comprise Plexaris or Cevaris which are EVs or exosomes, respectively.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts
• A61K 35/19 - PlateletsMegacaryocytes
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 47/02 - Inorganic compounds
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions

Abstract

The invention relates to the isolation or extraction of exosomes.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
• B01D 15/08 - Selective adsorption, e.g. chromatography
• B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
• B01J 20/26 - Synthetic macromolecular compounds
• B01J 20/32 - Impregnating or coating
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
• B01J 39/26 - Cation exchangers for chromatographic processes
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

The present invention relates to fluorescent dyes of formula (I), including salts thereof, and extracellular vesicles and cells labelled with the fluorescent dyes. The present invention also relates to methods, uses and kits thereof. (Formula (I))

IPC Classes  ?

• C09B 55/00 - Azomethine dyes
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
• A61K 49/00 - Preparations for testing in vivo
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper

Abstract

The present invention provides an extracellular vesicle (EV) comprising an EV defining an inner-vesicle space, a transmembrane protein displaying an attachment site on the surface of the EV, a targeting molecule attached to the attachment site of the transmembrane protein, thereby targeting the EV to a target cell, and an anti-viral therapeutic agent located in or on the inner-vesicle space. The present invention provides methods of preparing such EVs and their methods of use.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/12 - Antivirals

Abstract

The invention provides methods and compositions for the isolation or extraction of exosomes or microvesicles. The methods and compositions may involve providing a device including exosome-binding ligands in the form of anionic or electron-rich groups arranged on a substrate surface. The methods and compositions may involve providing a device including a substrate having a surface, with a plurality of polymers attached to the substrate and exosome-binding ligands in the form of anionic or electron-rich groups arranged on the plurality of polymers.

IPC Classes  ?

• B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

The invention relates to the isolation or extraction of exosomes.

IPC Classes  ?

• B01D 15/08 - Selective adsorption, e.g. chromatography
• B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
• B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
• B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
• B01J 39/26 - Cation exchangers for chromatographic processes
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• B01J 20/26 - Synthetic macromolecular compounds
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• B01J 20/32 - Impregnating or coating
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Goods & Services

Therapeutic pharmaceutical for the treatment of orthopaedic conditions including sarcopenia, osteoarthritis and tendinopathy, degenerative eye disease including age related macular degeneration, age related conditions, neurodegenerative disease, depression, bleeding, trauma, stroke, heart disease; protein arrays and polypeptides for diagnosing age-related conditions including joint and tendon degeneration, cardio-vascular diseases, degenerative bone conditions and neurodegeneration, radiation induced tissue degeneration and impairments in trauma-induced healing.

Abstract

The invention relates to the isolation or extraction of exosomes.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
• B01D 15/08 - Selective adsorption, e.g. chromatography
• B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
• B01J 20/26 - Synthetic macromolecular compounds
• B01J 20/32 - Impregnating or coating
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
• B01J 39/26 - Cation exchangers for chromatographic processes
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

The invention provides methods and compositions for the isolation or extraction of exosomes or microvesicles. The methods and compositions may involve providing a device including exosome-binding ligands in the form of anionic or electron-rich groups arranged on a substrate surface. The methods and compositions may involve providing a device including a substrate having a surface, with a plurality of polymers attached to the substrate and exosome-binding ligands in the form of anionic or electron-rich groups arranged on the plurality of polymers.

IPC Classes  ?

• G01N 1/34 - PurifyingCleaning
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor

Goods & Services

Cellular function activating agents for medical purposes; therapeutic pharmaceutical for the treatment of wounds, skin conditions, orthopaedic conditions including sarcopenia, osteoarthritis and tendinopathy, degenerative eye disease including age related macular degeneration, age related conditions, neurodegenerative disease, depression, bleeding, trauma, stroke, heart disease.

Goods & Services

Cellular function activating agents for medical purposes; therapeutic pharmaceutical for the treatment of wounds, skin conditions, orthopaedic conditions including sarcopenia, osteoarthritis and tendinopathy, degenerative eye disease including age related macular degeneration, age related conditions, neurodegenerative disease, depression, bleeding, trauma, stroke, heart disease.

Goods & Services

Cellular function activating agents for medical purposes; therapeutic pharmaceutical for the treatment of wounds, skin conditions, orthopaedic conditions including sarcopenia, osteoarthritis and tendinopathy, degenerative eye disease including age related macular degeneration, age related conditions, neurodegenerative disease, depression, bleeding, trauma, stroke, heart disease

Goods & Services

Therapeutic pharmaceutical for the treatment of wounds, skin conditions, orthopaedic conditions including sarcopenia, osteoarthritis and tendinopathy, degenerative eye disease including age related macular degeneration, age related conditions, neurodegenerative disease, depression, bleeding, trauma, stroke, heart disease.

Goods & Services

Cellular function activating agents for medical purposes.

Abstract

The invention relates to the isolation or extraction of exosomes.

IPC Classes  ?

• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• A61K 35/66 - Microorganisms or materials therefrom